Drug intelligence / Profile preview

compound 27

Development stage: Preclinical
Modality: Small Molecules

Overview

Compound 27 is an optimized IRAK1/4/pan-FLT3 kinase inhibitor. It demonstrates potent and selective inhibition of Interleukin-1 receptor-associated kinase 1 (IRAK1), Interleukin-1 receptor-associated kinase 4 (IRAK4), and Fms-like tyrosine kinase 3 (FLT3). The drug candidate exhibits reduced hERG block and good pharmacokinetic properties. In preclinical studies, specifically a mouse xenograft model of acute myeloid leukemia (AML), compound 27 has shown superior survival prolongation compared to gilteritinib, an FDA-approved FLT3 inhibitor used for AML treatment.

Targets

IRAK4 (Interleukin-1 receptor associated kinase 4)IRAK1 (Interleukin-1 receptor-associated kinase 1)FLT3 (Fms related receptor tyrosine kinase 3)

Beyond the preview

Go deeper on compound 27.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on compound 27.

Explore the full profile